Endpoints News runs a recurring Endpoints 100 (E100) survey that polls a group of top biotech and biopharma executives on market conditions, policy, financing, and the outlook for the industry.13
A 2025 E100 discussion highlights that by the second half of 2025 there is “cautious optimism” in biotech, with signs that the market is recovering, dealmaking is up, and the IPO window has cracked open again.2
The central question Endpoints poses for this E100 cycle is whether top biotech execs are feeling good about the road ahead or are still wary of jinxing the recovery, reflecting a more upbeat but still measured sentiment.2
The 2025 E100 conversations are framed against a backdrop of industry instability, including changes at the FDA, broader US health policy under the Trump administration, and geopolitical issues such as China–US tensions and tariffs, all of which shape executives’ views on regulation, costs, and supply chains.13
Endpoints uses the E100 survey results in live panel events where industry leaders interpret the data and discuss trends in financing, policy, AI, and drug development, giving a qualitative layer to the more quantitative survey findings.123
Earlier E100 survey work around H1 2025 focused on how Trump 2.0, FDA reorganization, and a tariff war were affecting biotech, with executives voicing concerns about regulatory uncertainty and economic risk, providing the baseline from which the later, more upbeat sentiment emerges.3
The E100 series also tracks how CEOs changed biotech operating models during the pandemic, with a view that “things will never be the same,” which informs how leaders assess resilience and opportunity in the current, somewhat improved environment.4
Sources:
1. https://events.endpts.com/the-endpoints-100-survey-2025
2. https://endpoints.studio/events/
3. https://events.endpts.com/e100-april2025
4. https://healtheconomics.com/the-endpoints-100-survey-ceos-changed-the-way-biotechs-operate-during-the-pandemic-things-will-never-be-the-same/